MARKET

CARA

CARA

Cara
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.13
-0.56
-2.84%
After Hours: 19.13 0 0.00% 16:41 10/18 EDT
OPEN
19.60
PREV CLOSE
19.69
HIGH
19.61
LOW
18.95
VOLUME
396.53K
TURNOVER
--
52 WEEK HIGH
27.55
52 WEEK LOW
12.19
MARKET CAP
887.97M
P/E (TTM)
-8.8360
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CARA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CARA News

  • Cara to increase enrollment in second late-stage study of Korsuva in CKD-aP
  • seekingalpha.4d ago
  • Cara to increase enrollment in second late-stage study of Korsuva in CKD-aP
  • Seeking Alpha - Article.4d ago
  • Cara Therapeutics' Interim Assessment of its KALM-2 Phase 3 Trial Results in the Size of the Trial Being Increased by 20%
  • Benzinga.4d ago
  • Cara Therapeutics Announces Completion of Interim Statistical Assessment and Small Increase in Target Enrollment for KALM-2 Phase 3 Global Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus
  • GlobeNewswire.4d ago

More

Industry

Biotechnology & Medical Research
-1.17%
Pharmaceuticals & Medical Research
-0.94%

Hot Stocks

Name
Price
%Change

About CARA

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.
More

Webull offers Cara Therapeutics Inc (CARA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.